2021 Neurotech Leaders Forum

November 8-9, 2021

Embassy Suites, San Francisco Airport Waterfront and Zoom

Tentative Agenda (all times PST) 

Day One

8:00-8:30

Registration and Coffee

8:30-9:15

State of the Neurotechnology Industry: 2021

James Cavuoto, Editor and Publisher, Neurotech Reports
Neurotech Business Report Editor James Cavuoto provides his insights and observations on the state of the neurotechnology industry. He surveys changes in the competitive landscape that have occurred over the years, the most significant events of the last year, and challenges confronting the industry in years ahead.
9:15-10:00

Keynote Address

Warren Grill, Ph.D., Edmund Pratt School Professor of Biomedical Engineering, Duke University
10:00-10:30

Refreshment Break

10:30-11:15

Neuromodulation Exits: The Outlook for IPOs and M&A

Jeremy Koff, Senior Consulting Editor, Neurotech Reports, Moderator
Paul Grand, CEO, MedTech Innovator
Mike Thomas, Senior Commercialization Officer, DARPA/In-Q-Tel
Amy Kruse, Ph.D., General Partner, Prime Movers Lab
Venture capital investors in startup and early-stage neuromodulation firms have had much cause for celebration in recent times. In this session, we'll discuss the ongoing outlook for successful exits and how that impacts investment decisions.
11:15-12:00

Neuromodulation Battlegrounds: Insurgents Seek to Capture Share from Incumbents

James Cavuoto, Editor, Neurotech Reports, Moderator
Victor Pikov, Ph.D., President and CEO, Medipace
Jeremy Koff, Senior Consulting Editor, Neurotech Reports
Dan Brounstein, Senior Vice-President, Saluda Medical
Several industry sectors have seen increased competition in recent years as neuromodulation newcomers have offered new therapeutic approaches for indications like OAB, OSA, and chronic pain. In this session, we'll survey the competitive landscape and the outlook for new entrants.   
12:00-1:30

Luncheon, Sponsored by Cirtec Medical

1:30-3:00

Neurotechnology Entrepreneur Panel

James Cavuoto, Editor, Neurotech Reports, Moderator
Brad Schmidt, Ph.D., CEO, Panaxium SAS
David Gray, Ph.D., CSO, Inscopix, Inc.
Richard Hanbury, CEO, Sana Health
Ash Attia, CEO, Bionic Vision Technologies
This session features presentations from CEOs and executives of several neurotechnology start-up firms and more established technology ventures. Each executive will present an overview of their firm's technology and markets.
3:00-3:30

Refreshment Break

3:30-4:15

Sensing the Future: New Advances in Diagnostics and Analytics

Jo Jo Platt, Contributing Editor, Neurotech Reports, Moderator
Brian Pepin, CEO, Rune Labs
Erika Ross, Ph.D., Director, Applied Research & Development, Abbott Neuromodulation
Pierre Wijdenes, Ph.D., CEO & Co-founder, Neurara
New neuromodulation therapies are exploiting advances in neurosensing technologies and novel biomarkers. In this session, we'll explore the value that diagnostic and analytical tools can bring to the neurotechnology industry.
4:15-5:00

Taking Our Medicine: Engaging Big Pharma in Neurotech

Susan Schaeffer, Consulting Editor, Neurotech Reports, Moderator
Lisa Shafer, Ph.D., CSO, Cerebral Therapeutics
Eric Grigsby, M.D., Founder and CEO, Neurovations
Elliot Krames, M.D., Former President, International Neuromodulation Society
With a few notable exceptions, the pharmaceutical industry has been on the sidelines as the neurotech industry has evolved. In this session, we'll explore the opportunities for interacting with big pharma in the yerars ahead.
5:00-7:00

Cocktail Reception, Sponsored by MST

 
 

 

Day Two

8:00:8:30

Registration and Coffee

8:30-9:15

Facing the Public: An Editorial Perspective

James Cavuoto, Editor and Publisher, Neurotech Reports, Moderator
Jeremy Koff, Senior Consulting Editor, Neurotech Reports
Jo Jo Platt, Contributing Editor, Neurotech Reports
In this session, Neurotech Reports team of editors will offer their views on recent controversies facing the neuromodulation industry, including ethical concerns, dealing with bad press, and legislative and regulatory developments.
9:15-10:00

Keynote Address

Dave Anderson, President, Medtronic Neuromodulation
10:00-10:30

Coffee Break

10:30-11:15

Paying it Forward: Reimbursement Trends for Neurotech Devices 

Jeremy Koff, Senior Consulting Editor, Neurotech Reports, Moderator
Mark Domyahn, Partner, JD Lymon
Courtney Lane, Ph.D., Principal, Anacapa Clinical Research
Implanted neuromodulation devices are doomed to failure if there's not a clear path to reimbursement. In this session, we'll look at recent decisions by CMS and private insurers relating to neurotech devices. 
11:15-12:00

Wearing it Proud: Noninvasive Neuromodulation Melds with the Wardrobe

Jo Jo Platt, Contributing Editor, Neurotech Reports, Moderator
Jon Sakai, Director, Commercialization, Cionic
Heather Verran, Faculty Advisor, Fashion Institute of Technology
Devjani Saha, Ph.D., Director, Neurology Regulatory Affairs, MCRA
Wearable devices promise to transform the neuromodulation industry in a profound way. In this session, we'll examine recent technology and fashion trends to see where the greatest potential lies.
12:00-1:30

Luncheon, Sponsored by Cirtec Medical

Presentation of 2021 Gold Electrode Awards
1:30-3:00

Neurotechnology Entrepreneur Panel

James Cavuoto, Editor, Neurotech Reports, Moderator
Luca Ravagnan, Ph.D., CEO, WISE Srl
Manfred Franke, Founder, NeuronOff Inc.
Nick Halper, Ph.D., Co-founder, Braingrade
Scott Hiatt, CTO, IRIS Biomedical
This session features presentations from CEOs and executives of several neurotechnology start-up firms and more established technology ventures. Each executive will present an overview of their firm's technology and markets.
3:00-3:30

Refreshment Break

3:30-4:15

The Incredible Shrinking Device: Neurostimulation's Fantastic Voyage 

James Cavuoto, Editor, Neurotech Reports, Moderator
Jon Ruais, Chief Commercial & Strategy Officer, Nalu Medical Inc.
Jason Pope, M.D., President and CEO, Evolve Restorative Center
Khalid Ishaque, Chief of Strategy, Bioinduction Ltd
Implantable neuromodulation devices continue to shrink in size and level of invasiveness. In this session, we'll look at advances such as flexible, stretchable, leads, injectable stimulators, and nanotech devices. 
4:15-5:00

A Terrible Market to Waste: Neuromodulation Conquers the Mind 

Jo Jo Platt, Contributing Editor, Neurotech Reports, Moderator
Brett Wingeier, Ph.D., CEO, Magnus Medical
Daniel Powell, CEO, Spark Biomedical
Scott Burwell, Ph.D., CEO, Neurotype Inc.
Psychiatric disorders such as major depression, Alzheimer's, and addiction represent perhaps the final frontier for the neuromodulation industry. In this closing session, we'll examine new implantable and noninvasive technologies on the horizon for treating cognitive and mood disorders.
5:00-7:00

Cocktail Reception, Sponsored by MST

 
 

 

      

©2021 Neurotech Reports. All rights reserved.